MannKind Discontinues Phase 3 Trial for Nontuberculous Mycobacterial Lung Disease Treatment MannKind Corporation announced today the discontinuation of its Phase 3 ICoN-1 clinical trial evaluating a nebulized formulation of clofazimine …
@2025 – Hosted by ByoHosting – Most Recommendeed Webhhosting. For complains, abuse, advertising contact: [email protected]